Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Late-Stage Pipeline

67%

2 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 4
2(100.0%)
2Total
Phase 4(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT07572032Phase 4Not Yet Recruiting

Delayed Initiation of ARNI and SGLT2i in Heart Failure With Corrected Aetiology (DELAY-HF), Pilot Study

Role: collaborator

NCT06622603Phase 4Recruiting

the Effects of Febuxostat Dose Tapering in Gout Patients Optimally Controlled for 5 Years or More

Role: collaborator

NCT06726226Recruiting

Extremely Preterm Respiratory Outcome Cohort

Role: collaborator

All 3 trials loaded